Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report
IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1470387/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832086483970818048 |
|---|---|
| author | Urpo Kiiskinen Grace Segall Hollie Bailey Cameron Forshaw Tarun Puri |
| author_facet | Urpo Kiiskinen Grace Segall Hollie Bailey Cameron Forshaw Tarun Puri |
| author_sort | Urpo Kiiskinen |
| collection | DOAJ |
| description | IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-positive NSCLC.MethodsThis observational study was conducted in 2020 in nine countries using electronic patient record forms, following Adelphi Disease Specific Programme (DSP™) methodology. Patients with advanced NSCLC (aNSCLC) were included in the overall cohort. A smaller RET fusion-positive cohort comprised patients from the overall aNSCLC cohort who had RET fusion-positive disease and no other co-alterations, plus an oversample of patients with RET fusion-positive disease and no other co-alterations.ResultsPatient characteristics were generally similar between the overall aNSCLC cohort (n=2947) and the RET fusion-positive cohort (n=576), aside from higher proportions of White/Caucasian patients, never smokers, and adenocarcinoma among the RET fusion-positive cohort. For the overall aNSCLC cohort, 899 (31%) were tested for RET fusions; 84% of RET test results were available prior to initiation of aNSCLC treatment. Comparisons between the two cohorts showed similar proportions of patients treated with chemotherapy (± immunotherapy), but less use of immunotherapy only or targeted therapy in the RET fusion-positive cohort.ConclusionsResults of this real-world study provide insights into clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-positive aNSCLC and highlight the need for awareness and education to increase RET testing with the intent to treat with selective RET inhibitors when appropriate to optimize outcomes for patients. |
| format | Article |
| id | doaj-art-126d8cbd318e40759233e5f932731b11 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-126d8cbd318e40759233e5f932731b112025-02-06T13:56:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.14703871470387Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief reportUrpo Kiiskinen0Grace Segall1Hollie Bailey2Cameron Forshaw3Tarun Puri4Eli Lilly and Company, Indianapolis, IN, United StatesEli Lilly and Company, Indianapolis, IN, United StatesAdelphi Real World, Bollington, Cheshire, United KingdomAdelphi Real World, Bollington, Cheshire, United KingdomEli Lilly and Company, Indianapolis, IN, United StatesIntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-positive NSCLC.MethodsThis observational study was conducted in 2020 in nine countries using electronic patient record forms, following Adelphi Disease Specific Programme (DSP™) methodology. Patients with advanced NSCLC (aNSCLC) were included in the overall cohort. A smaller RET fusion-positive cohort comprised patients from the overall aNSCLC cohort who had RET fusion-positive disease and no other co-alterations, plus an oversample of patients with RET fusion-positive disease and no other co-alterations.ResultsPatient characteristics were generally similar between the overall aNSCLC cohort (n=2947) and the RET fusion-positive cohort (n=576), aside from higher proportions of White/Caucasian patients, never smokers, and adenocarcinoma among the RET fusion-positive cohort. For the overall aNSCLC cohort, 899 (31%) were tested for RET fusions; 84% of RET test results were available prior to initiation of aNSCLC treatment. Comparisons between the two cohorts showed similar proportions of patients treated with chemotherapy (± immunotherapy), but less use of immunotherapy only or targeted therapy in the RET fusion-positive cohort.ConclusionsResults of this real-world study provide insights into clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-positive aNSCLC and highlight the need for awareness and education to increase RET testing with the intent to treat with selective RET inhibitors when appropriate to optimize outcomes for patients.https://www.frontiersin.org/articles/10.3389/fonc.2025.1470387/fullclinical characteristicstreatment patternsbiomarker testingRET fusion-positive non-small cell lung cancerreal-world data |
| spellingShingle | Urpo Kiiskinen Grace Segall Hollie Bailey Cameron Forshaw Tarun Puri Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report Frontiers in Oncology clinical characteristics treatment patterns biomarker testing RET fusion-positive non-small cell lung cancer real-world data |
| title | Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report |
| title_full | Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report |
| title_fullStr | Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report |
| title_full_unstemmed | Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report |
| title_short | Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report |
| title_sort | characteristics treatment patterns and biomarker testing of patients with advanced ret fusion positive non small cell lung cancer in a real world multi country observational study a brief report |
| topic | clinical characteristics treatment patterns biomarker testing RET fusion-positive non-small cell lung cancer real-world data |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1470387/full |
| work_keys_str_mv | AT urpokiiskinen characteristicstreatmentpatternsandbiomarkertestingofpatientswithadvancedretfusionpositivenonsmallcelllungcancerinarealworldmulticountryobservationalstudyabriefreport AT gracesegall characteristicstreatmentpatternsandbiomarkertestingofpatientswithadvancedretfusionpositivenonsmallcelllungcancerinarealworldmulticountryobservationalstudyabriefreport AT holliebailey characteristicstreatmentpatternsandbiomarkertestingofpatientswithadvancedretfusionpositivenonsmallcelllungcancerinarealworldmulticountryobservationalstudyabriefreport AT cameronforshaw characteristicstreatmentpatternsandbiomarkertestingofpatientswithadvancedretfusionpositivenonsmallcelllungcancerinarealworldmulticountryobservationalstudyabriefreport AT tarunpuri characteristicstreatmentpatternsandbiomarkertestingofpatientswithadvancedretfusionpositivenonsmallcelllungcancerinarealworldmulticountryobservationalstudyabriefreport |